Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation

Acta Medica Austriaca

Volumn 23, Issue 3, 1996, Pages 85-91

  Hajek R ^a   Adam, Z ^a   Vasova I ^a   Kral Z ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

bone marrow transplantation; chemotherapy; interferon alpha; multiple myeloma

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; MULTIPLE MYELOMA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; HUMANS; INTERFERON-ALPHA; MELPHALAN; MULTIPLE MYELOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029832932     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Adam Z, Elbl L, Vorlíček J, Hájek R, et al: Treatment of refractory multiple myeloma with vincristin, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD). Acta Med Austriaca 1994;21:111-115.
2. Adam Z., Vorlíek J, Králová E, et al: Terapie mnohocetného myelomu (Therapy of multiple myeloma). Press: Masaryk University Brno 1993, pp 1-220.
3. Adkins DR, Salzman D, Boldt D, et al: Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. J Clin Oncol 1991;12:1890-1901.
4. Ahre A, Bjorkholm M, Mellstedt H, et al: Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984;68:1331-1338.
5. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
6. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-89.
7. Alexanian R, Dimopoulos MA. Management of multiple myeloma. Sem Oncol 1995;32:20-30.
8. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-890.
9. Alexanian R, Dimopoulos MA, Hester J, et al: Early myeloablative therapy for multiple myeloma. Blood 1994;84:4278-4282.
10. Alexanian R, Dimopoulos M, Smith T, et al: Limited value of myeloablative therapy for late multiple myeloma. Blood 1994;83:512-516.
11. Alexanian R, Haut A, Khan A, et al: Treatment for multiple myeloma combination therapy with different melphalan dose regimens. J Am Med Ass 1969;208:1680-1685.
12. Anderson KC, Andersen J, Soiffer R, et al: Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993;82:2568-2576.
13. Attal M, Harousseau IL, Stoppa AM, et al: High dose therapy in multiple myeloma: a prospective randomized study of the Intergroupe Francais du Myelome. Blood 1993;82:198a (abstr 776).
14. Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggresive myeloma. Blood 1992;79:1130-1136.
15. Barlogie B, Hall R, Zander A, et al: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298-1301.
16. Barlogie B, Jagannath S, Vesole D and Tricot G: Autologous and allogeneic transplants for multiple myeloma. Sem Oncol 1995;32:31-44.
17. Barlogie B, Smith L, Alexanian R: Fffective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
18. Bensinger WI, Appelbaum F, Clift R, et al: Allogenic marrow transplantation for multiple myeloma, an analysis of risk factors for outcome. 4th International Workshop on Multiple Myeloma, Oct 1993; Mayo Clinic: 94.
19. Bensinger WI, Buckner CD, Clift RA, et al: Phase I study of busulfan and cyclophosphamide for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992;10:1492-1497.
20. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogenic blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658.
21. Bird JM, Russell NH, Samson D, et al: Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivals. Bone Marrow Transplant 1993;12:651-654.
22. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-448.
23. Browman GP, Rubin S, Walker I, et al: Interferon-alpha-2b (IFN) maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma (PMC): Results of a randomized trial. Proc Am Soc Clin Oncol 1994;13:408 (abstr 1391).
24. Cavo M, Tura S, Rosti G, et al: Allogenic BMT for multiple myeloma (MM). The Italian experience. Bone Marrow Transplant 1991;7 (suppl 2): 31.
25. Crowley J, Jagannath S, Salmon S, et al: Standard VAD (SWOG 8624) versus total therapy (TT) with 2 autotransplant (AT) for untreated multiple myeloma (MM). Proc Am Soc Clin Oncol 1994;12:410 (abstr 1401).
26. Cunningham D, Paz-Ares L, Gore ME, et al: High-dose melphalan for multiple myeloma: Long-term follow-up data. J Clin Oncol 1994;12:764-768.
27. Cunningham D, Powles R, Malpas JS, et al: A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 1993;12:364 (abstr 1232).
28. Cunningham D, Powles R, Viner, et al: High dose chemotherapy and autologous bone marrow transplantation in multiple myeloma. 4th International Workshhop on Multiple Myeloma, Rochester, MN, USA 1993; 102 (abstr).
29. Demuynck H, Delforge M, Verhoef G, et al: Comparative study of peripheral progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combinated with rhGM-CSF or rh-CSF. Br J Haematol 1995;90:384-392.
30. Dimopoulos MA, Alexanian R, Przepiorka D, et al: Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;15:2324-2328.
31. Durie BGM, Gale RP, Klein JP, et al: Allogeneic bone marrow transplants for multiple myeloma: an IBMTR analysis. Proc Am Soc Clin Oncol 1995;13:426 (abstr 1358).
32. Fermand JP, Chevret S, Ravaud P, et al: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993;82:2005-2009.
33. Fermand JP, Levy Y, Gerota J, et al: Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20-23.
34. Forgeson GV, Selby P, Lakhani S, et al: Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated myeloma patients. Br J Cancer 1988;58:469-473.
35. Gahrton G, Tura S, Ljungman P, et al: Prognostic factor in allogeneic bone marrow transplantation in multiple myeloma. J Clin Oncol 1995;13:1312-1322.
36. Gazitt Y, Reading C, Lee J-H, et al: Diferential peripheral blood mobilization of tumor and normal hematopoietic progenitor cells (HPC) in multiple myeloma (MM). Blood 1995;84 (suppl 1): 354a (abstr 1400).
37. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;11:580-585.
38. Goldman J: Peripheral blood stem cells for allografting. Blood 1995;85:1413-1415.
39. Gore ME, Selby PJ, Viner C, et al: Intensive treatment of multiple myeloma and criteria for complete remission (see comments). Lancet 1989;11:879-882.
40. Gregory W, Richards M, Malpas J: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-342.
41. Harousseau JC, Attal M, Divine M, et al: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood, 1995;85:3077-3085.
42. Harousseau JL, Milpied N, Lapone JP, et al: Double-intensive therapy in high-risk multiple myeloma. Blood 1992;79:2827-2833.
43. Hussein MA, Smith HJ, Tubbs R, et al: In-vivo effect of GM-CSF on myeloma cell cycling. Proc Am Soc Clin Oncol 1995;13:427 (abstr 1360).
44. Jagannath S, Barlogie B, Dicke KA, et al: Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 1990;76:1860-1866.
45. Jagannath S, Barlogie B, Vesole D, et al: Two hundred sixty autotransplant (TX) for multiple myeloma (MM)-Prognostic factor analysis. Blood 1993;82:198a (abstr 779).
46. Jagannath S, Crowley J, Vesole D, et al: Interferon-alpha (IFN) may improve event-free (EFS) and overall survival (OS ) in multiple myeloma (MM) following double autotransplants (DAT). Proc Am Soc Clin Oncol 1995;14:425 (abstr 1354).
47. Jagannath S, Vesole DH, Glenn L, et al: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992;80:1666-1672.
48. Jagannath S, Vesole DH, Tricot G, Barlogie B: Total Therapy. ABMTR, Newsletter 1995;10:9-13.
49. Klumpp TR: Complication of peripheral blood stemm cell transplantation. Sem Oncol 1995;22:263-270.
50. Kohno A, Takeyama K, Narabayashi M, et al: Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995;15:49-54.
51. Körbling M, Przepiorka D, Huh YO, et al: Allogenic blood stem cell transplantation for refractory leukemia and lymphoma. Blood 1995;85:1659-1665.
52. Ludwig H, Cohen AM, Polliac A, et al: Interferon alfa for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-476.
53. Ludwig H, Cortelezzi A, Scheithauer W, et al: Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986;22:1111-1116.
54. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;322:1430-1434.
55. Mayer J, Vorlíek J: Transplantation of haematopoietic stem cells of peripheral blood. Part 3. Vnitrní lékarství, Praha 1995;41:266-270.
56. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983;11:822-824.
57. ( 57) McNiece I, Glaspy J, LeMaistre F, et al: Effects of recombinant methionyl human stem cell factor and filgrastim (rh-G-CSF) on mobilization of peripheral blood progenitor cells: Preliminary laboratory results from a phase I/II study. Blood 1993;82:84a(abstr).
58. McSweeney EN, Tobias JS, Blackman G, et al: Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol 1993;5:378-383.
59. Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, et al: Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Bone Marrow Transplant 1994;13:37-41.
60. Peest D, Deicher H, Coldewey R, et al: Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988;24:1061-1067.
61. Porter DL, Roth MS, McGarigle, et al: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100.
62. Reece DE, Shepherd JD, Klingemann HG, et al: Treatment of myeloma using intesive therapy and allogenic bone marrow transplantation. Bone Mar Trans 1995;15:117-123.
63. Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2405-2414.
64. Samson D, Gaminara E, Newland A, et al: Infusion of vincristine and doxorubicine with oral dexamethasone as first-line treatment for multiple myeloma. Lancet 1989;11:882-885.
65. Schiller G, Nimer S, Vescio G, et al: Phase I-II study of busulfan and cyclophospahmide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 1994;14:131-136.
66. Schiller G, Vescio R, Freytes C, et al: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86:390-397.
67. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogenic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-1672.
68. Stadtmauer EA, Scheider CHJ, Silberstein LE: Peripheral blood progenitor cell generation and harvestin. Sem Oncol 1995;22:291-300.
69. Tricot G, Jagannath S, Vesole D, et al: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.
70. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, Runen FFH: The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994;30A:457-459.
71. Varterasian M, Ratanatharathorn V, Karanes G, et al: Bone marrow transplantation for multiple myeloma: the Wayne State Experience. Bone Mar Transplant 1995;14:328-329.
72. Vesole DH, Barlogie B, Jagannath S, et al: High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994;84:950-956.
73. Vesole DH, Jagannath S, Glenn LD, et al: Allogenic bone marrow transplantation in multiple myeloma (MM). Proc Am Soc Clin Oncol 1993;11:405 (abstr 1386).
74. Vesole DH, Jagannath S, Tricot, et al: High-dose intesive therapy with autologous transplantation (AT) in multiple myeloma (MM) patients over age 60. Proc Am Soc Clin Oncol 1994;13:410 (abstr 1400).
75. Westin J: Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. Sem Oncol 1991;18 (suppl 7):37-40.
76. Zhang B X-G, Bataille R, Jourdan M, et al: Granulocyte-Macrophage Colony-Stimulating Factor synergizes with Interleukin-6 in supporting the proliferation of human meloma cells. Blood 1990;76:2599-2605.